Mendelian’s flagship product MendelScan, searches electronic health records for indicators of rare, or hard to diagnose diseases. Algorithms developed from published diagnostic criteria are used to flag patients at risk and a clinical report is generated, providing suggested next steps to take in the diagnostic pathway.

Find your nearest AHSN



MendelScan meets the key objectives of the NHS Long Term strategy such as enabling earlier diagnosis, and better outcomes for rare disease patients. It also aligns with the UK Framework for rare disease, in particular, the first priority: improving rare disease diagnosis and the underlying theme - better use of data and digital technologies.

How did the Innovation Exchange help?

Mendelian was part of the 2020-21 DigitalHealth.London Accelerator programme, which supported MendelScan’s Health Economics case, by helping build a Budget Impact Model looking at the possible savings to the system.

The team were successful in applying for Primary Care Digital Health Evidence Pitching Event, co-sponsored by DigitalHealth.London and were able to pitch their research evidence generation plans to a group of primary care researchers – a collaboration with an established academic group is currently being finalised.

Impact & Outcomes

MendelScan is currently being implemented in multiple NHS practices, with a roll out to more than one million patients planned in late 2021/ early 2022. Mendelian is also working with two Genetic Medicine Service Alliances, and they will be deploying MendelScan in partnership with local genetic services.

Mendelian has recently partnered with Ipsen Pharmaceuticals to support the faster diagnosis of rare diseases across the NHS, additionally, the team have several other commercial partnerships in final stages of contracting.